التفاصيل البيبلوغرافية
| العنوان: |
Adjusted Comparison of Outcomes between Patients from CARTITUDE-1 versus Multiple Myeloma Patients with Prior Exposure to PI, Imid and Anti-CD-38 from a German Registry. |
| المؤلفون: |
Merz, Maximilian, Goldschmidt, Hartmut, Hari, Parameswaran, Agha, Mounzer, Diels, Joris, Ghilotti, Francesca, Perualila, Nolen J., Cabrieto, Jedelyn, Haefliger, Benjamin, Sliwka, Henrik, Schecter, Jordan M., Jackson, Carolyn C., Olyslager, Yunsi, Akram, Muhammad, Nesheiwat, Tonia, Kellermann, Lenka, Jagannath, Sundar |
| المصدر: |
Cancers; Dec2021, Vol. 13 Issue 23, p5996, 1p |
| مصطلحات موضوعية: |
THERAPEUTIC use of protease inhibitors, THERAPEUTIC use of monoclonal antibodies, REPORTING of diseases, THERAPEUTICS, CONFIDENCE intervals, CELLULAR therapy, ATTITUDE (Psychology), HEALTH outcome assessment, CELL receptors, CANCER patients, COMPARATIVE studies, IMMUNOLOGICAL adjuvants, SURVIVAL analysis (Biometry), DESCRIPTIVE statistics, MULTIPLE myeloma, INTENTION, LONGITUDINAL method, PROBABILITY theory, PROPORTIONAL hazards models, EVALUATION |
| مصطلحات جغرافية: |
GERMANY |
| مستخلص: |
Simple Summary: There is an urgent need to develop new treatments for patients with relapsed/refractory multiple myeloma (RRMM) to address unmet medical needs. Chimeric antigen receptor T-cell (CAR-T) therapy is a novel approach with the potential for long-term disease control. Ciltacabtagene autoleucel (cilta-cel) is a CAR-T treatment studied in patients with RRMM in the CARTITUDE-1 clinical trial and has shown clinically important effects. However, CARTITUDE-1 was a single arm study. The current study compared outcomes for cilta-cel with an external cohort of German patients that are similar to the ones in CARTITUDE-1 to compare the effectiveness of cilta-cel versus established clinical practice. To overcome potential bias, individual patient data were used to adjust for the differences in patient characteristics between cohorts. The results showed substantially better outcomes for cilta-cel on both overall survival and the time to next treatment. These findings highlight cilta-cel's potential as a novel, effective treatment to address unmet treatment needs. Ciltacabtagene autoleucel (cilta-cel) is a Chimeric antigen receptor T-cell therapy with the potential for long-term disease control in heavily pre-treated patients with relapsed/refractory multiple myeloma (RRMM). As cilta-cel was assessed in the single-arm CARTITUDE-1 clinical trial, we used an external cohort of patients from the Therapie Monitor registry fulfilling the CARTITUDE-1 inclusion criteria to evaluate the effectiveness of cilta-cel for overall survival (OS) and time to next treatment (TTNT) vs. real-world clinical practice. Individual patient data allowed us to adjust the comparisons between both cohorts, using the inverse probability of treatment weighting (IPW; average treatment effect in the treated population (ATT) and overlap population (ATO) weights) and multivariable Cox proportional hazards regression. Outcomes were compared in intention-to-treat (HR, IPW-ATT: TTNT: 0.13 (95% CI: 0.07, 0.24); OS: 0.14 (95% CI: 0.07, 0.25); IPW-ATO: TTNT: 0.24 (95% CI: 0.12, 0.49); OS: 0.26 (95% CI: 0.13, 0.54)) and modified intention-to-treat (HR, IPW-ATT: TTNT: 0.24 (95% CI: 0.09, 0.67); OS: 0.26 (95% CI: 0.08, 0.84); IPW-ATO: TTNT: 0.26 (95% CI: 0.11, 0.59); OS: 0.31 (95% CI: 0.12, 0.79)) populations. All the comparisons were statistically significant in favor of cilta-cel. These results highlight cilta-cel's potential as a novel, effective treatment to address unmet needs in patients with RRMM. [ABSTRACT FROM AUTHOR] |
|
Copyright of Cancers is the property of MDPI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder